Cadila receives audit closure report
The Moraiya manufacturing plant had completed the USFDA audit from February 6th to 15th 2017 with Zero 483 observations, the company said.
MUMBAI: Ahmedabad based Zydus Cadila’s on Wednesday said that the company has received an establishment inspection report (EIR) from the USFDA, that signifies a successful closure of the audit for its Moraiya facility.The Moraiya manufacturing plant had completed the USFDA audit from February 6th to 15th 2017 with Zero 483 observations, the company said. Post the audit, the plant has received several product approvals, including the final approval to market the anti inflammatory drug Mesalamine tablets in the US.
Shares of Cadila remained neutral to the development.
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions